Halozyme Therapeutics, Inc. (HALO) Market Cap & Valuation Ratios
Halozyme Therapeutics, Inc. (HALO) has a market cap of $14.3B, a trailing P/E of 36.6 and a price-to-sales ratio of 8.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HALOHalozyme Therapeutics, Inc.Follow HALO — free
—
Price chart with a free account
- Market cap
- 14.3B
- P/E TTM
- 36.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| HALO | 14 | 36.6 | 9.8 | 26.5 | 5.7% | +41% | 36% | 22% |
| INSM | 20 | — | 17.4 | — | -4.0% | +186% | -74% | -133% |
| EXEL | 16 | 20.3 | 6.2 | 15.2 | 7.3% | +9% | 40% | 47% |
| ASND | 15 | — | — | — | — | +113% | 25% | 11% |
| JAZZ | 14 | 14.6 | 3.6 | 10.3 | 10.3% | +13% | 19% | 9% |
| BBIO | 13 | — | 21.3 | — | -3.2% | +202% | -70% | — |
| SMMT | 12 | — | — | — | -3.7% | — | — | -513% |
| TECH | 11 | 63.1 | 9.3 | 32.4 | 2.3% | -0.4% | 21% | 9% |
| BMRN | 11 | 151.2 | 4.2 | 46.8 | 6.8% | +11% | 4% | 1.0% |
| MDGL | 10 | — | 7.4 | — | -2.1% | +149% | -25% | -54% |
| CORT | 9.3 | 204.4 | 10.8 | 1110.0 | 1.2% | +16% | 0.8% | 0.9% |
| Median of these 10 | 63.1 | 8.4 | 32.4 | 1.2% | +16% | 4% | 1.0% |
P/E 36.6 vs. a peer median of 63.1; EV/Sales 9.8 vs. 8.4. HALO's own P/E sits at the 97th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesINSM and ASND and BBIO and SMMT and MDGL have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Halozyme Therapeutics, Inc. — questions
- What is Halozyme Therapeutics, Inc.'s market cap?
- $14.3B.
- What is Halozyme Therapeutics, Inc.'s P/E ratio?
- 36.6 on trailing twelve-month earnings to 2026-06-30.
- What is Halozyme Therapeutics, Inc.'s price-to-sales ratio?
- 8.6.
Every figure on this page comes from Halozyme Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.